Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).

被引：0
|
作者：
Kozioff, M.
Sledge, G. W.
Benedetti, F. M.
Starr, A.
Wallace, J. A.
Stuart, M. J.
Gruver, D.
Miller, K.
机构：
[1] Ingalls Hosp, Harvey, IL USA
[2] Univ Chicago, Harvey, IL USA
[3] Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA
[4] Genon Corp, Menlo Pk, CA USA
[5] Monroe Med Assoc, Harvey, IL USA
[6] Univ Chicago, St Marys Hosp, Monroe Med Assoc, Chicago, IL 60637 USA
[7] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2598
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Lapatinib (L) in Combination With Paclitaxel (P) is an Effective and Tolerable Treatment in HER2-overexpressing Metastatic Breast Cancer (MBC) Patients
    Guan, Z.
    Xu, B.
    DeSilvio, M.
    Newstat, B.
    Moore, Y.
    Makhson, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S345 - S345
  • [42] A PHASE II EVALUATION OF LAPATINIB (L) AND BEVACIZUMAB (B) IN HER2+METASTATIC BREAST CANCER (MBC)
    Dickler, M.
    Franco, S.
    Stopeck, A.
    Ma, W.
    Lyandres, J.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Rugo, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 65 - 65
  • [43] A phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2+metastatic breast cancer (MBC)
    Rugo, H. S.
    Franco, S.
    Munster, P.
    Stopeck, A.
    Ma, W.
    Lyandres, J.
    Lahiri, S.
    Arbushites, M.
    Koehler, M.
    Dickler, M. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [44] Randomized study comparing nab-paclitaxel with solvent- based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC)
    Guan, Z.
    Feng, F.
    Li, Q. L.
    Jiang, Z.
    Shen, Z.
    Yu, S.
    Feng, J.
    Huang, J.
    Yao, Z.
    Hawkins, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Phase 1b study of motesanib diphosphate (AMG 706) in combination with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer
    Kaufman, P. A.
    de Boer, R.
    White, S.
    Mainwaring, P.
    Koczwara, B.
    Drury, S.
    Ye, Y.
    Sun, Y-N
    Sikorski, R.
    Kotasek, D.
    CANCER RESEARCH, 2009, 69 (02) : 285S - 286S
  • [46] A phase II study of HER3-DXD in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, E. P.
    Bagegni, N. A.
    Beck, J. T.
    Cultrera, J. L.
    Dosunmu, O.
    Gwin, W. R.
    Heeke, A. L.
    Khoury, K.
    Sellami, D.
    Shastry, M.
    Sternberg, D. W.
    Toppmeyer, D.
    Wright-Browne, V. M.
    Yuan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S220 - S220
  • [47] Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study
    R. Delva
    T. Pienkowski
    N. Tubiana
    U. Vanhoefer
    B. Longerey
    I. Douville
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 703 - 709
  • [48] Oral vinorelbine/paclitaxel combination treatment of metastatic breast cancer: a phase I study
    Delva, R.
    Pienkowski, T.
    Tubiana, N.
    Vanhoefer, U.
    Longerey, B.
    Douville, I.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (06) : 703 - 709
  • [49] A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC)
    Hamilton, Erika P.
    Dosunmu, Ololade
    Shastry, Mythili
    Finney, Lindsey
    Sellami, Dalila B.
    Sternberg, David W.
    Wright-Browne, Vance
    Toppmeyer, Deborah
    Gwin, William R.
    Thaddeus, J. Thaddeus
    Cultrera, Jennifer L.
    Bagegni, Nusayba Ali
    Khoury, Katia
    Heeke, Arielle Lutterman
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Phase I study of the combination of balixafortide (CXCR4 inhibitor) and eribulin in HER2-negative metastatic breast cancer (MBC) patients (pts).
    Gil-Martin, Marta
    Pardo, Patricia Gomez
    Lopez-Tarruella, Sara
    Manso, Luis
    Perez-Fidalgo, Jose Alejandro
    Ademuyiwa, Foluso Olabisi
    Mayer, Ingrid A.
    Pluard, Timothy J.
    Garcia, Maria Martinez
    Kaufman, Peter A.
    Vandat, Linda T.
    Hooftman, Leon W.
    Romagnoli, Barbara
    Hernando, Cristina
    Weilbaecher, Katherine N.
    Ciruelos, Eva M.
    Martin, Miguel
    Simon, Sonia Pernas
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345